Kestra Medical affiliate share sales reported

Kestra Medical Technologies reported Form 144 notice showing affiliate sales.

Rhea-AI Filing Summary

Kestra Medical Technologies reported Form 144 notice showing affiliate sales. Brian Webster reported selling common shares in three transactions: 12/29/2025 ($398,847.04), 01/15/2026 ($342,023.69), and 02/17/2026 ($384,020.06), each for 15,000 common shares. The filing also records a restricted share issuance of 15,000 shares on 01/21/2026 granted under the issuer's equity compensation plan.

Insights

Securities Compliance Counsel

Routine Form 144 affiliate sales and a concurrent restricted grant are disclosed.

The filing lists three reported dispositions by Brian Webster of 15,000 common shares each on 12/29/2025, 01/15/2026, and 02/17/2026, with gross proceeds shown as $398,847.04, $342,023.69, and $384,020.06 respectively. These are sale notices, not company purchases.

Timing and amounts are explicit in the excerpt; cash‑flow treatment (who received proceeds) and whether sales were pursuant to a trading plan are not stated in the provided excerpt. Subsequent filings may clarify any trading-plan disclosures or net-of-tax mechanics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What sales does KMTS Form 144 show for Brian Webster?

The filing reports three sales of 15,000 shares each by Brian Webster on 12/29/2025, 01/15/2026, and 02/17/2026. Gross proceeds reported were $398,847.04, $342,023.69, and $384,020.06 respectively.

Did KMTS issue any restricted shares in the period covered?

Yes. The excerpt shows a restricted share issuance of 15,000 common shares to Kestra Medical Technologies, Ltd. on 01/21/2026, granted under the issuer's equity compensation plan.

Does the Form 144 excerpt state who received sale proceeds?

The provided excerpt lists gross proceeds for each sale but does not state who received the proceeds or how they were distributed. The cash‑flow recipient is not specified in the excerpt.

Are these Form 144 entries indicative of company stock offerings?

No. The entries are affiliate sale notices and a restricted grant under an equity plan; they do not constitute a company public offering. The filing documents individual dispositions and a compensation grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 06:17 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001877188
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	KESTRA MEDICAL TECHNOLOGIES, LTD.
SEC File Number	001-42549
Address of Issuer	3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WASHINGTON 98033
Phone	(425) 279-8002
Name of Person for Whose Account the Securities are To Be Sold	Webster Brian Daniel
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Shares	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	15000	304123.49	58373353	03/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	01/21/2026	Restricted share issuance	KESTRA MEDICAL TECHNOLOGIES, LTD.			15000	01/21/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Brian Webster 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Shares	12/29/2025	15000	398847.04
Brian Webster 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Shares	01/15/2026	15000	342023.69
Brian Webster 3933 LAKE WASHINGTON BLVD NE SUITE 200 KIRKLAND WA 98033	Common Shares	02/17/2026	15000	384020.06

144: Remarks and Signature

Remarks
Date of Notice	03/17/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/29/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Brian Webster
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)